Oral ivermectin versus malathion lotion for difficult-to-treat head lice

New England Journal of Medicine

Volumn 362, Issue 10, 2010, Pages 896-905

  Chosidow, Olivier ^a,c   Giraudeau, Bruno ^b,d   Cottrell, Jeremy ^f   Izri, Arezki ^e   Hofmann, Robert ^h   Mann, Stephen G ^f   Burgess, Ian ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f McNeil   (United Kingdom)

^g Cambridgeshire   (United Kingdom)

^h JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN; MALATHION;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEDICULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77949368548     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0905471     Document Type: Article

References (41)

1. Roberts RJ. Head lice. N Engl J Med 2002;346:1645-50.
2. Dodd CS. Withdrawn: interventions for treating head lice. Cochrane Database Syst Rev 2007;4:CD001165.
3. Vander Stichele RH, Dezeure EM, Bogaert MG. Systematic review of clinical efficacy of topical treatment for head lice. BMJ 1995;311:604-8.
4. Malathion for treatment of head lice. Med Lett Drugs Ther 1999;41:73-4.
5. Chosidow O. Scabies and pediculosis. Lancet 2000;355:819-26.
6. Chosidow O, Chastang C, Brue C, et al. Controlled study of malathion and d-phenothrin lotions for Pediculus humanus var capitis-infested schoolchildren. Lancet 1994;344:1724-7.
7. Burgess IF, Brown CM, Peock S, Kaufman J. Head lice resistant to pyrethroid insecticides in Britain. BMJ 1995;311:752.
8. Mumcuoglu KY, Hemingway J, Miller J, et al. Permethrin resistance in the head louse Pediculus capitis from Israel. Med Vet Entomol 1995;9:427-32.
9. Pollack RJ, Kiszewski A, Armstrong P, et al. Differential permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med 1999;153:969-73.
10. Meinking TL, Serrano L, Hard B, et al. Comparative in vitro pediculicidal efficacy of treatments in a resistant head lice population in the United States. Arch Dermatol 2002;138:220-4.
11. Hunter JA, Barker SC. Susceptibility of head lice (Pediculus humanus capitis) to pesticides in Australia. Parasitol Res 2003; 90:476-8.
12. Vassena CV, Mougabure Cueto G, González Audino P, Alzogaray RA, Zerba EN, Picollo MI. Prevalence and levels of permethrin resistance in Pediculus humanus capitis De Geer (Anoplura: Pediculidae) from Buenos Aires, Argentina. J Med Entomol 2003;40:447-50.
13. Lee SH, Yoon KS, Williamson MS, et al. Molecular analysis of kdr-like resistance in permethrin-resistant strains of head lice, Pediculus capitis. Pestic Biochem Physiol 2000;66:130-43.
14. Kristensen M, Knorr M, Rasmussen AM, Jespersen JB. Survey of permethrin and malathion resistance in human head lice populations from Denmark. J Med Entomol 2006;43:533-8.
15. Burgess IF, Brown CM, Lee PN. Treatment of head louse infestation with 4% dimeticone lotion: randomized controlled equivalence trial. BMJ 2005;330:1423-6.
16. Heukelbach J, Pilger D, Oliveira FA, Khakban A, Ariza L, Feldmeier H. A highly efficacious pediculicide based on dimeticone: randomized observer blinded comparative trial. BMC Infect Dis 2008;8:115.
17. Roberts RJ, Casey D, Morgan DA, Petrovic M. Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial. Lancet 2000;356:540-4.
18. Elston DM. Controversies concerning the treatment of lice and scabies. J Am Acad Dermatol 2002;46:794-6.
19. Chosidow O. Bug Buster for head lice: is it effective? Arch Dermatol 2006;142: 1635-7.
20. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med 1995; 333:26-30.
21. Foucault C, Ranque S, Badiaga S, Rovery C, Raoult D, Brouqui P. Oral ivermectin in the treatment of body lice. J Infect Dis 2006;193:474-6.
22. Mumcuoglu KY, Miller J, Rosen LJ, Galun R. Systemic activity of ivermectin on the human body louse (Anoplura: Pediculidae). J Med Entomol 1990;27:72-5.
23. Glaziou P, Nyguyen LN, Moulia-Pelat JP, Cartel JL, Martin PM. Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994;45: 253-4.
24. Mumcuoglu KY, Friger M, Ioffe-Uspensky I, Ben-Ishai F, Miller J. Louse comb versus direct visual examination for the diagnosis of head louse infestation. Pediatr Dermatol 2001;18:9-12.
25. Morikawa T, Yoshida M. A useful test-ing strategy in phase III trials: combined test of superiority and test of equivalence. J Biopharm Stat 1995;5:297-306.
26. Donner A, Klar N. Design and analysis of cluster randomization trials. London: Arnold, 2000.
27. Giraudeau B. Model mis-specification and overestimation of the intraclass correlation coefficient in cluster randomized trials. Stat Med 2006;25:957-64.
28. Menegaux F, Baruchel A, Lescoeur B, et al. Household exposure to pesticides and risk of childhood acute leukaemia. Occup Environ Med 2006;63:131-4.
29. Yoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Arch Dermatol 2003;139:994-1000.
30. Strycharz JP, Yoon KS, Clark JM. A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae). J Med Entomol 2008; 45:75-81.
31. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-5.
32. del Giudice P, Marty P, Gari-Toussaint M, Le Fichoux Y. Ivermectin in elderly patients. Arch Dermatol 1999;135:351-2.
33. Roulet A, Puel O, Gesta S, et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003;460:85-91.
34. Gardon J, Gardon-Wendel N, Demanga-Ngange, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350:18-22.
35. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2008; 2(10):e317.
36. Bourguinat C, Pion SD, Kamgno J, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 2007;1(1):e72.
37. Heukelbach J, Winter B, Wilcke T, et al. Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Health Organ 2004;82:563-71.
38. Chosidow O. Scabies. N Engl J Med 2006;354:1718-27.
39. Badiaga S, Foucault C, Rogier C, et al. The effect of a single dose of oral ivermectin on pruritus in the homeless. J Antimicrob Chemother 2008;62:404-9.
40. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 2004;39(1): e8-e12.
41. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabiesendemic communities. Arch Dermatol 2009;145:840-1.